CRP and hepatocellular carcinoma: Consistently, HCC patients characterised as CRP flare-responders or CRP responders experienced higher ORR (78.9% or 78.4% versus 48.4% for non-responders) and DCR (94.8% or 96.7% versus 78.1% for non-responders) than those with CRP non-responders in the whole cohort.